Pyxis Oncology’s (PYXS) “Buy” Rating Reaffirmed at Jefferies Financial Group

Jefferies Financial Group reiterated their buy rating on shares of Pyxis Oncology (NASDAQ:PYXS) in a research report released on Tuesday, MarketBeat Ratings reports. The brokerage currently has a $10.00 price target on the stock.

Other equities research analysts have also issued research reports about the company. HC Wainwright reiterated a buy rating and issued a $7.00 price objective on shares of Pyxis Oncology in a research note on Wednesday, April 10th. Royal Bank of Canada restated an outperform rating and issued a $7.00 price objective on shares of Pyxis Oncology in a report on Friday, March 22nd. Leerink Partnrs reissued an outperform rating on shares of Pyxis Oncology in a report on Tuesday, January 23rd. SVB Leerink assumed coverage on Pyxis Oncology in a report on Tuesday, January 23rd. They set an outperform rating and a $12.00 price target for the company. Finally, BTIG Research started coverage on Pyxis Oncology in a research report on Friday, February 9th. They set a buy rating and a $8.00 target price on the stock. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of Buy and an average target price of $8.80.

Pyxis Oncology Price Performance

PYXS stock opened at $4.38 on Tuesday. Pyxis Oncology has a 1 year low of $1.35 and a 1 year high of $6.85. The firm has a market capitalization of $257.89 million, a PE ratio of -2.38 and a beta of 1.45. The business has a 50 day simple moving average of $5.00 and a 200-day simple moving average of $3.39.

Pyxis Oncology (NASDAQ:PYXS) last released its quarterly earnings results on Thursday, March 21st. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.16. On average, equities research analysts expect that Pyxis Oncology will post -0.85 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Commonwealth Equity Services LLC acquired a new position in shares of Pyxis Oncology during the 3rd quarter worth $26,000. Acadian Asset Management LLC acquired a new position in Pyxis Oncology during the third quarter worth $26,000. Schulhoff & Co. Inc. acquired a new position in shares of Pyxis Oncology during the 3rd quarter worth $44,000. SG Americas Securities LLC purchased a new stake in Pyxis Oncology in the 1st quarter valued at approximately $59,000. Finally, Radcliffe Capital Management L.P. acquired a new position in shares of Pyxis Oncology in the third quarter valued at approximately $106,000. Hedge funds and other institutional investors own 39.09% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma.